VERSANTIS
Versantis is a Swiss pharmaceutical company developing medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide. Its lead candidate, VS-01, is currently at the preclinical stage and has the potential to be the first drug for acute liver disease simultaneously supporting multiple failing organs. VS-01 targets 3 rare indications and received an... Orphan Drug Designation in ALF. In addition, Versantis’ pipeline promises to improve patients’ outcomes in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities and significant upsides for Versantis. Versantis was established in 2015 by Meriam Kabbaj in Zurich, Switzerland.
VERSANTIS
Industry:
Health Care Health Diagnostics Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Zürich, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.versantis.ch
Total Employee:
1+
Status:
Active
Contact:
+41446330672
Email Addresses:
[email protected]
Total Funding:
21.11 M CHF
Technology used in webpage:
SPF ReCAPTCHA Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS ReCAPTCHA V2 DMARC Websense
Similar Organizations
TCR2
TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuCâ„¢ platform.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Vaxxit
Vaxxit is a biopharmaceutical company developing vaccines against HIV.
Current Advisors List
Current Employees Featured
Founder
Investors List
Innosuisse
Innosuisse investment in Grant - Versantis
Swisscanto Private Equity
Swisscanto Private Equity investment in Series B - Versantis
Healthequity
Healthequity investment in Series B - Versantis
Esperante Ventures
Esperante Ventures investment in Series B - Versantis
Verve Ventures
Verve Ventures investment in Series B - Versantis
Zürcher Kantonal Bank
Zürcher Kantonal Bank investment in Series B - Versantis
redalpine
redalpine investment in Series B - Versantis
OCCIDENT
OCCIDENT investment in Series A - Versantis
Healthequity
Healthequity investment in Series A - Versantis
Zürcher Kantonal Bank
Zürcher Kantonal Bank investment in Series A - Versantis
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-19 | Versantis Appoints Leading Hepatologist Prof Dr Katharina Staufer as Chief Medical Officer |
Official Site Inspections
http://www.versantis.ch
- Host name: genlamplb002.prj-su6ko8.alias.fr.clara.net
- IP address: 79.99.38.44
- Location: Lambersart France
- Latitude: 50.6453
- Longitude: 3.0404
- Timezone: Europe/Paris
- Postal: 59130
More informations about "Versantis"
Versantis - Crunchbase Company Profile & Funding
Versantis is a Swiss pharmaceutical company developing medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive …See details»
Versantis AG - Swiss Biotech
Versantis is a clinical-stage company developing transformative orphan drugs that fill the medical gap in the care of liver and pediatric diseases. It has been acquired by GENFIT in 2022. VS-01 …See details»
Versantis AG - Venturelab
Mar 18, 2015 · Versantis is a global, clinical-stage pharmaceutical company addressing the growing, un-met medical need in liver diseases. Our lead program VS-01 leverages our …See details»
Versantis | ETH Zurich - ETH Zürich
Founded in 2015, Versantis has pioneered drug treatments of acute-on-chronic liver failure (ACLF). In 2022, they were acquired by GENFIT to further consolidate their position as a …See details»
Versantis AG - Venture Kick
Dec 28, 2021 · Versantis is a global, clinical-stage pharmaceutical company addressing the growing, un-met medical need in liver diseases. Our lead program VS-01 leverages our proprietary scavenging liposomes technology to timely …See details»
Versantis AG - startup.ch
Versantis is a global, clinical-stage pharmaceutical company addressing the growing, un-met medical need in liver diseases. Our lead program VS-01 leverages our proprietary scavenging liposomes technology to timely reverse …See details»
Taking the fight against liver diseases to the next level
Oct 20, 2022 · ETH spin- off Versantis is dedicated to the fight against liver diseases. Their lead drug candidate gives hope to a rising number of affected patients. Co- founder Vincent Forster talks about a great opportunity, which …See details»
Versantis AG Company Profile | Zürich, ZÜRICH, Switzerland ...
Find company research, competitor information, contact details & financial data for Versantis AG of Zürich, ZÃœRICH. Get the latest business insights from Dun & Bradstreet.See details»
Versantis to be acquired by GENFIT, combining forces to continue …
Sep 19, 2022 · Versantis today announced its planned acquisition by GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic …See details»
Versantis Company Profile 2024: Valuation, Investors, …
Operator of a drug development company intended to develop disruptive therapies for rare liver and pediatric diseases.See details»
GENFIT acquires Swiss biotech Versantis for up to CHF105 million
Sep 19, 2022 · The acquisition of Versantis fits perfectly within GENFIT’s strategic vision of becoming a global leader in ACLF (acute-on-chronic liver failure). As a pioneer in ACLF, …See details»
Versantis COO Meriam Kabbaj: ‘The most rewarding aspect of …
Nov 2, 2021 · Our series about Switzerland’s most inspiring entrepreneurs and founders continues with Meriam Kabbaj, the co-founder and COO of Versantis. The ETH Zurich spin-off …See details»
Versantis Company Profile - Office Locations, Competitors, …
Versantis is a developer of liver disease therapeutics and diagnostics intended to provide the first drug capture platform for the treatment of life-threatening intoxications.See details»
Versantis Raises CHF 4.4 Million in Series A Financing to Advance …
Mar 29, 2017 · Versantis, a pharmaceutical company focused on the development of products addressing a high unmet medical need in the diagnosis, prevention, and treatment of liver …See details»
Versantis celebrates successful first-in-human trial - startupticker.ch
Mar 17, 2021 · The company’s lead candidate, VS-01 is a lipid-based, potentially lifesaving, multi-organ support therapy that aims to reverse Acute-on-Chronic Liver Failure (ACLF) by …See details»
Vincent Forster – CEO, Versantis - PharmaBoardroom
Aug 16, 2021 · Dr Vincent Forster of Versantis, a Swiss biotech aiming to develop a new generation of liver disease therapeutics and diagnostics, introduces the company's foundation …See details»
Versantis to Present Positive Phase 1b Data at AASLD for VS-01 in ...
Nov 15, 2021 · VS-01 is a potentially lifesaving, multi-organ support therapy that aims to timely reverse Acute-on-Chronic Liver Failure (ACLF) by enhancing the clearance of ammonia and …See details»
Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, …
Dec 20, 2021 · ZURICH-- ( BUSINESS WIRE )--Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, today announced …See details»
Versantis AG - top100startup.ch
Jan 3, 2021 · Versantis is a global, clinical-stage pharmaceutical company addressing the growing, un-met medical need in liver diseases. Our lead program VS-01 leverages our …See details»
Versantis Raises CHF 4.4 Million in Series A Financing to Advance …
Mar 29, 2017 · Versantis, a pharmaceutical company focused on the development of products addressing a high unmet medical need in the diagnosis, prevention, and treatment of liver …See details»